Notably, in Figure 3C, the effectiveness of the sequential administration of IL-13-LCL-SIM (administered on days 7 and 10 after tumor cell inoculation) and PEG-EV-DOX (administered on days 8 and 11 after tumor cell inoculation) was demonstrated, by reducing tumor growth almost totally compared to the control untreated group, by 94% (p < 0,0001) and having a stronger antitumor effect than each of the single therapies, by 80% reduction compared to the IL-13-LCL-SIM-treated group, and by 73% reduction compared to the PEG-EV-DOX-treated group (p < 0.05). This evidence concerns the gene IL13 and neoplasm.